Goodwill and Intangible Assets

12 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

5.	GOODWILL AND INTANGIBLE ASSETS

Goodwill

The Company has recorded goodwill of $195.3 from the acquisitions of Sividon Diagnostics that was completed on May 31, 2016, GmbH, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $129.9 relates to the Company’s diagnostic segment and $65.4 related to the other segment. The Company assessed goodwill for impairment in accordance with the appropriate guidance (see Note 1) and recorded no impairment of goodwill for the period ended June 30, 2016, 2015 and 2014. Included in the diagnostic segment is $17.7 in goodwill associated with the acquisition of Sividon which is preliminary and subject to adjustment within the measurement period (see Note 2).

The following summarizes changes to the goodwill balance for the years ended June 30, 2016 and 2015:


	Years Ended June 30,
	2016			2015
Beginning balance	$	177.2		$	169.2
Acquisitions		17.7			8.1
Translation adjustments		(0.2	)		(0.1	)
Measurement period adjustments (see note 2)		0.6			(0.1	)

Ending balance	$	195.3		$	177.1

Intangible Assets

Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, developed technology, a laboratory database, trademarks, and customer relationships as well as non-amortizable intangible assets of in-process technologies, research and development. Certain of these intangible assets were recorded as part of the Company’s purchase of Sividon on March 31, 2016, Crescendo on February 28, 2014 and Myriad RBM on May 31, 2011. The Company’s developed technology and database acquired have estimated remaining useful lives between 16 and 20 years, trademarks acquired have an estimated remaining useful life of approximately 13 years and customer relationships have an estimated remaining useful life of approximately 6 years. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company concluded there was no impairment of long-lived assets for the years ended June 30, 2016, 2015 and 2014.

The following summarizes the amounts reported as intangible assets:


	Gross Carrying Amount		Accumulated Amortization			Net
At June 30, 2016:
Purchased licenses and technologies	$	228.7	$	(28.5	)	$	200.2
Customer relationships		4.7		(2.4	)		2.3
Trademarks		3.0		(0.6	)		2.4

Total amortizable intangible assets		236.4		(31.5	)		204.9

In-process research and development		22.6		—			22.6

Total unamortized intangible assets		22.6		—			22.6

Total intangible assets	$	259.0	$	(31.5	)	$	227.5


	Gross Carrying Amount		Accumulated Amortization			Net
At June 30, 2015:
Purchased licenses and technologies	$	199.1	$	(16.7	)	$	182.4
Customer relationships		4.7		(1.9	)		2.8
Trademarks		3.0		(0.4	)		2.6

Total amortizable intangible assets		206.8		(19.0	)		187.8

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(19.0	)	$	192.6

As of June 30, 2016 the weighted average remaining amortization period for purchased licenses and technologies, trademarks, and customer relationships is approximately 15 years.

The Company recorded amortization during the respective periods for these intangible assets as follows:


	Years Ended June 30,
	2016		2015		2014
Amortization on intangible assets	$	12.6	$	12.7	$	4.6

Amortization expense of intangible assets is estimated to be $14.2 in 2017, $14.2 in 2018, $14.2 in 2019, $13.8 in 2020 and $13.8 in 2021 and $134.7 thereafter.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details